Clinical trial
Post-Marketing Surveillance of Halaven Injection in Korean Patients
NCT02441764 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-Marketing Surveillance of Halaven Injection in Korean Patients
- Lead sponsor
- Eisai Korea Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2013
- Completion date
- August 31, 2018
- Enrollment
- 3,000 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer